Merck reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. But Merck posted a modest 2026 outlook that ...

Merck forecasts 2026 sales below Wall Street estimates Co plans to offer clarity on $70 billion growth opportunities by 2027 Merck anticipates $2.5 billion impact from generic competition, Medicare ...

Merck on Tuesday revealed a lower-than-expected outlook for 2026 as the drugmaker aims to remake its business before its powerhouse cancer drug loses patent protection in a few years. The stock MRK ...

Merck is rated Buy after extending Keytruda's patent protection to late-2029, delaying the anticipated patent cliff, and unlocking significant near-term value. The extended exclusivity creates a ...

Merck headquarters in Rahway, NJ. RAWAY, N.J. – Merck today announced fourth quarter earnings and revenue that beat Wall Street estimates. However, Merck, the giant pharmaceutical company with ...

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its post-Keytruda future with what it foresees as a host of major sales ...

Merck (MRK) shares slid about 3% in premarket trading on Tuesday after the drugmaker issued a full-year 2026 outlook that came in below Wall Street expectations. The Rahway, New Jersey–based company ...

Robert Davis, Merck CEO, joins 'Mad Money' host Jim Cramer to talk quarterly results, global sales growth, recent acquisitions, and more. Got a confidential news tip? We want to hear from you. Sign up ...

Merck recorded higher revenue in its fourth quarter, but expects earnings growth to slow as it ramps up acquisitions. The healthcare company on Tuesday posted a profit of $2.96 billion, or $1.19 a ...

Merck could lose up to $630 million in Gardasil revenue this year now that the U.S. no longer recommends three doses of the HPV shot in the childhood vaccine schedule, according to Jefferies analysts.

Merck (MRK) has beaten earnings in 8 consecutive quarters with an average surprise of 5.1%. Ten Merck executives purchased $15.98M in stock seven days before earnings. Merck’s Keytruda sales reached ...